1. BOYLE P, SEVERI G.: Epidemiology of prostate cancer. Chemoprevention.

Eur Urol 1999;

35: 370-376.
2. ARRIZABALAGA M, NAVARRO M, MORAS J y cols.: Incidencia de los principales carcinomas
urológicos en el área sanitaria VII de Madrid. Actas Urológicas Españolas 1994: 145: 161.
3. Migowski A SG. Survival and prognostic factors of patients with clinically localized prostate
cancer. RevSaúde Pública 2010; 44(2): 344-52
4. Organización Panamericana de la Salud. Cáncer en las Américas. Perfiles de país, 2013.
Washington, D.C.: 2013.
5. Matiz, José Luis Poveda, et al. "Evolución de la mortalidad por cáncer de próstata en
Colombia: estudio ecológico." Urología Colombiana 23.1 (2014): 3-10.
6. Velásquez, Esteban. Cáncer de próstata continúa en aumento en Colombia. Redacción
Social 2015.
7. Guía práctica clínica. Diagnóstico y tratamiento del cáncer de próstata en el segundo y
tercer nivel de atención. Consejo de salubridad general 2009.
8. Ruiz J. Relación de la susceptibilidad genética y de las características anatomopatológicas
del cáncer de próstata con los polimorfismos de nucleótido simple. Universidad Autónoma
de Barcelona 2012.
9. American Urological Association Education and Research, Inc. website. PSA testing for the
pretreatment staging and posttreatment management of prostate cancer: 2013 Revision
of 2009 Best Practice Statement. www.auanet.org/guidelines/prostate-specific-antigen-
(2009-amended-2013). Accessed October 9, 2017.
10. Leitzmann MF, Platz EA, Stampfer MJ, Willett WC, Giovannucci E. "Ejaculation frequency
and subsequent risk of prostate cancer." Journal JAMA, 2004, páginas 1578-86, Vol. 291
PMID 15069045
11. Miller, DC, Hafez, KS, Stewart, A, et al. "Prostate carcinoma presentation, diagnosis, and
staging: an update form the National Cancer Data Base." Cancer 2003; 98:1169. PMID
12973840
12. Singh D, Febbo PG, Ross K, Jackson DG, Manola J, Ladd C, et al. Gene expression correlates
of clinical prostate cancer behavior. Cancer Cell. 2002;1(2):203-9.
13. Bubendorf L, Kolmer M, Kononen J, Koivisto P, Mousses S, Chen Y, et al. Hormone therapy
failure in human prostate cancer: analysis by complementary DNA and tissue microarrays.
J Natl Cancer Inst. 1999 20;91(20):1758-64.
14. Rubin MA, Zhou M, Dhanasekaran SM, Varambally S, Barrette TR, Sanda MG, et al. alpha-
Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA. 2002
3;287(13):1662-70
15. Andriole GL, Crawford ED, Grubb RL, 3rd, Buys SS, Chia D, Church TR, et al. Mortality
results from a randomized prostate-cancer screening trial. N Engl J Med. 2009
26;360(13):1310-9.
16. De Marzo AM, Marchi VL, Epstein JI, Nelson WG. Proliferative inflammatory atrophy of the
prostate: implications for prostatic carcinogenesis. Am J Pathol. 1999;155(6):1985-92.
17. Nupponen NN, Visakorpi T. Molecular cytogenetics of prostate cancer. Microsc Res Tech.
2000 1;51(5):456-63.
18. Yano S, Matsuyama H, Matsuda K, Matsumoto H, Yoshihiro S, Naito K. Accuracy of an array
comparative genomic hybridization (CGH) technique in detecting DNA copy number
aberrations: comparison with conventional CGH and loss of heterozygosity analysis in
prostate cancer. Cancer Genet Cytogenet. 2004 15;150(2):122-7.
19. Papadopoulos N, Kinzler KW, Vogelstein B. The role of companion diagnostics in the
development and use of mutation-targeted cancer therapies. Nat Biotechnol.
2006;24(8):985-95.